Founded in 2021, TerThera strives to meet the growing global demand for radionuclides in cancer healthcare by providing a highly sustainable and uninterrupted supply of Terbium-161 for use in radioligand therapy.
The scarcity of radionuclides for use in radioligand therapy impacts the lives of many cancer patients, with a secured stock of highly enriched gadolinium-160 our team promises to deliver therapeutic quantities of GMP-grade Terbium-161, expanding the options available for patient treatments.
Having resolved the scarcity of Terbium-161, we aim to enable Terbium-161 radioligand therapy by supporting academic partners, preclinical, and clinical research towards patient treatment, ultimately working towards understanding the underlying mechanisms of internal radiation therapy.